factuality_value
stringclasses 7
values | predicat@xml:space
stringclasses 1
value | predicat@charOffset
stringlengths 3
9
| predicat@headOffset
stringlengths 3
9
| predicat@id
stringclasses 206
values | predicat@text
stringlengths 2
124
| predicat@type
stringclasses 29
values | predicat@charOffsetMin
int64 0
3.96k
| predicat@charOffsetMax
int64 6
3.97k
| subject@xml:space
stringclasses 1
value | subject@charOffset
stringlengths 3
9
| subject@headOffset
stringlengths 3
9
| subject@id
stringclasses 197
values | subject@text
stringlengths 2
49
| subject@type
stringclasses 72
values | subject@charOffsetMin
int64 0
3.98k
| subject@charOffsetMax
int64 3
4k
| object@xml:space
stringclasses 1
value | object@charOffset
stringlengths 3
9
| object@headOffset
stringlengths 3
9
| object@id
stringclasses 198
values | object@text
stringlengths 2
53
| object@type
stringclasses 73
values | object@charOffsetMin
int64 0
3.93k
| object@charOffsetMax
int64 4
3.94k
| id
stringclasses 58
values | raw_sent_text
stringlengths 20
749
| sent_charOffset
stringlengths 4
9
| sent_charOffsetMin
int64 0
3.88k
| sent_charOffsetMax
int64 26
4.2k
| formated_sentence
stringlengths 34
768
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Fact | preserve | 1392-1404 | 1395-1404 | T98 | LA treatment | USES | 1,392 | 1,404 | preserve | 1395-1404 | 1395-1404 | T91 | treatment | TherapeuticOrPreventiveProcedure | 1,395 | 1,404 | preserve | 1392-1394 | 1392-1394 | T90 | LA | OrganicChemical | 1,392 | 1,394 | A28 | LA treatment was associated with increased SG in both diabetic groups (lean 1.28 +/- 0.14 to 1.93 +/- 0.13; obese 1.07 +/- 0.11 to 1.53 +/- 0.08 x 10(-2) min-1, P < 0.05). | 1392-1575 | 1,392 | 1,575 | @OBJECT$ @PREDICAT$ @SUBJECT$ was associated with increased SG in both diabetic groups (lean 1.28 +/- 0.14 to 1.93 +/- 0.13; obese 1.07 +/- 0.11 to 1.53 +/- 0.08 x 10(-2) min-1, P < 0.05). |
Fact | preserve | 90-100 | 90-100 | T11 | implicated | AFFECTS | 90 | 100 | preserve | 76-80 | 76-80 | T5 | iron | BiologicallyActiveSubstance | 76 | 80 | preserve | 104-122 | 110-122 | T6 | lipid peroxidation | MolecularFunction | 104 | 122 | A1 | Free iron has been implicated in lipid peroxidation and ischemic myocardial damage, and it has been suggested that iron is an independent risk factor for myocardial infarction. | 71-259 | 71 | 259 | Free @SUBJECT$ has been @PREDICAT$ in @OBJECT$ and ischemic myocardial damage, and it has been suggested that iron is an independent risk factor for myocardial infarction. |
Fact | preserve | 1092-1096 | 1092-1096 | T66 | risk | PREDISPOSES | 1,092 | 1,096 | preserve | 1042-1053 | 1047-1053 | T51 | iron intake | Finding | 1,042 | 1,053 | preserve | 1100-1121 | 1111-1121 | T53 | myocardial infarction | DiseaseOrSyndrome | 1,100 | 1,121 | A2 | Heme iron intake was positively associated with risk of myocardial infarction (relative risk for the highest vs. | 1037-1156 | 1,037 | 1,156 | Heme @SUBJECT$ was positively associated with @PREDICAT$ of @OBJECT$ (relative risk for the highest vs. |
Probable | preserve | 215-226 | 220-226 | T13 | risk factor | PREDISPOSES | 215 | 226 | preserve | 192-196 | 192-196 | T8 | iron | BiologicallyActiveSubstance | 192 | 196 | preserve | 237-258 | 248-258 | T10 | myocardial infarction | DiseaseOrSyndrome | 237 | 258 | A3 | Free iron has been implicated in lipid peroxidation and ischemic myocardial damage, and it has been suggested that iron is an independent risk factor for myocardial infarction. | 71-259 | 71 | 259 | Free iron has been implicated in lipid peroxidation and ischemic myocardial damage, and it has been suggested that @SUBJECT$ is an independent @PREDICAT$ for @OBJECT$ . |
Fact | preserve | 90-100 | 90-100 | T11 | implicated | AFFECTS | 90 | 100 | preserve | 76-80 | 76-80 | T5 | iron | BiologicallyActiveSubstance | 76 | 80 | preserve | 127-146 | 136-146 | T7 | ischemic myocardial | DiseaseOrSyndrome | 127 | 146 | A4 | Free iron has been implicated in lipid peroxidation and ischemic myocardial damage, and it has been suggested that iron is an independent risk factor for myocardial infarction. | 71-259 | 71 | 259 | Free @SUBJECT$ has been @PREDICAT$ in lipid peroxidation and @OBJECT$ damage, and it has been suggested that iron is an independent risk factor for myocardial infarction. |
Fact | preserve | 2673-2675 | 2673-2675 | T190 | as | compared_with | 2,673 | 2,675 | preserve | 2614-2634 | 2614-2634 | T176 | Diclofenac-potassium | OrganicChemical | 2,614 | 2,634 | preserve | 2676-2683 | 2676-2683 | T178 | placebo | MedicalDevice | 2,676 | 2,683 | A1 | Diclofenac-potassium seemed to be as well tolerated as placebo, with fewer adverse events reported than after sumatriptan treatment and with more patients assessing the overall tolerability of diclofenac-potassium better than that of sumatriptan. | 2614-2879 | 2,614 | 2,879 | @SUBJECT$ seemed to be as well tolerated @PREDICAT$ @OBJECT$ , with fewer adverse events reported than after sumatriptan treatment and with more patients assessing the overall tolerability of diclofenac-potassium better than that of sumatriptan. |
Fact | preserve | 2737-2758 | 2749-2758 | T193 | sumatriptan treatment | USES | 2,737 | 2,758 | preserve | 2737-2748 | 2737-2748 | T181 | sumatriptan | OrganicChemical | 2,737 | 2,748 | preserve | 2737-2748 | 2737-2748 | T181 | sumatriptan | OrganicChemical | 2,737 | 2,748 | A4 | Diclofenac-potassium seemed to be as well tolerated as placebo, with fewer adverse events reported than after sumatriptan treatment and with more patients assessing the overall tolerability of diclofenac-potassium better than that of sumatriptan. | 2614-2879 | 2,614 | 2,879 | Diclofenac-potassium seemed to be as well tolerated as placebo, with fewer adverse events reported than after @OBJECT$ @SUBJECT$ @PREDICAT$ and with more patients assessing the overall tolerability of diclofenac-potassium better than that of sumatriptan. |
Fact | preserve | 1459-1461 | 1459-1461 | T101 | in | TREATS | 1,459 | 1,461 | preserve | 1400-1407 | 1400-1407 | T88 | placebo | MedicalDevice | 1,400 | 1,407 | preserve | 1511-1518 | 1511-1518 | T94 | attacks | Finding | 1,511 | 1,518 | A5 | METHODS: Single oral doses of 50 mg and 100 mg diclofenac-potassium were compared to a single oral dose of 100 mg sumatriptan and placebo in a double-blind randomized crossover trial in 156 adult patients suffering from migraine attacks, with or without aura, selected according to the International Headache Society diagnostic criteria. | 1263-1625 | 1,263 | 1,625 | METHODS: Single oral doses of 50 mg and 100 mg diclofenac-potassium were compared to a single oral dose of 100 mg sumatriptan and @SUBJECT$ in a double-blind randomized crossover trial @PREDICAT$ 156 adult patients suffering from migraine @OBJECT$ , with or without aura, selected according to the International Headache Society diagnostic criteria. |
Fact | preserve | 874-918 | 913-918 | T66 | Diclofenac-potassium is a potent NSAID | ISA | 874 | 918 | preserve | 874-894 | 874-894 | T56 | Diclofenac-potassium | OrganicChemical | 874 | 894 | preserve | 913-918 | 913-918 | T58 | NSAID | PharmacologicSubstance | 913 | 918 | A6 | Diclofenac-potassium is a potent NSAID available as a fast-acting oral tablet, which has been shown to be safe and effective in several other acute pain indications. | 874-1051 | 874 | 1,051 | @SUBJECT$ @PREDICAT$ @OBJECT$ available as a fast-acting oral tablet, which has been shown to be safe and effective in several other acute pain indications. |
Fact | preserve | 1481-1490 | 1481-1490 | T103 | suffering | PROCESS_OF | 1,481 | 1,490 | preserve | 1536-1540 | 1536-1540 | T95 | aura | Finding | 1,536 | 1,540 | preserve | 1472-1480 | 1472-1480 | T92 | patients | PatientOrDisabledGroup | 1,472 | 1,480 | A7 | METHODS: Single oral doses of 50 mg and 100 mg diclofenac-potassium were compared to a single oral dose of 100 mg sumatriptan and placebo in a double-blind randomized crossover trial in 156 adult patients suffering from migraine attacks, with or without aura, selected according to the International Headache Society diagnostic criteria. | 1263-1625 | 1,263 | 1,625 | METHODS: Single oral doses of 50 mg and 100 mg diclofenac-potassium were compared to a single oral dose of 100 mg sumatriptan and placebo in a double-blind randomized crossover trial in 156 adult @OBJECT$ @PREDICAT$ from migraine attacks, with or without @SUBJECT$ , selected according to the International Headache Society diagnostic criteria. |
Fact | preserve | 611-627 | 616-627 | T38 | drug sumatriptan | ISA | 611 | 627 | preserve | 616-627 | 616-627 | T36 | sumatriptan | OrganicChemical | 616 | 627 | preserve | 611-615 | 611-615 | T35 | drug | PharmacologicSubstance | 611 | 615 | A8 | Although also sometimes used to treat migraine, nonsteroidal anti-inflammatory drugs (NSAIDs) have not been systematically evaluated in controlled clinical trials, particularly in comparison with the newer drug sumatriptan. | 393-628 | 393 | 628 | Although also sometimes used to treat migraine, nonsteroidal anti-inflammatory drugs (NSAIDs) have not been systematically evaluated in controlled clinical trials, particularly in comparison with the newer @OBJECT$ @PREDICAT$ @SUBJECT$ . |
Fact | preserve | 1459-1461 | 1459-1461 | T101 | in | TREATS | 1,459 | 1,461 | preserve | 1384-1395 | 1384-1395 | T87 | sumatriptan | OrganicChemical | 1,384 | 1,395 | preserve | 1511-1518 | 1511-1518 | T94 | attacks | Finding | 1,511 | 1,518 | A10 | METHODS: Single oral doses of 50 mg and 100 mg diclofenac-potassium were compared to a single oral dose of 100 mg sumatriptan and placebo in a double-blind randomized crossover trial in 156 adult patients suffering from migraine attacks, with or without aura, selected according to the International Headache Society diagnostic criteria. | 1263-1625 | 1,263 | 1,625 | METHODS: Single oral doses of 50 mg and 100 mg diclofenac-potassium were compared to a single oral dose of 100 mg @SUBJECT$ and placebo in a double-blind randomized crossover trial @PREDICAT$ 156 adult patients suffering from migraine @OBJECT$ , with or without aura, selected according to the International Headache Society diagnostic criteria. |
Fact | preserve | 1991-2019 | 2015-2019 | T135 | migraine headache pain | ISA | 1,991 | 2,019 | preserve | 1991-2014 | 2006-2014 | T129 | migraine headache | DiseaseOrSyndrome | 1,991 | 2,014 | preserve | 2015-2019 | 2015-2019 | T130 | pain | SignOrSymptom | 2,015 | 2,019 | A11 | FINDINGS: Diclofenac-potassium was more effective than placebo in reducing migraine headache pain at 2 h after dosing, which was the primary endpoint. | 1910-2072 | 1,910 | 2,072 | FINDINGS: Diclofenac-potassium was more effective than placebo in reducing @SUBJECT$ @PREDICAT$ @OBJECT$ at 2 h after dosing, which was the primary endpoint. |
Fact | preserve | 629-679 | 670-679 | T47 | Sumatriptan is a specific migraine treatment | ISA | 629 | 679 | preserve | 629-640 | 629-640 | T39 | Sumatriptan | OrganicChemical | 629 | 640 | preserve | 670-679 | 670-679 | T41 | treatment | TherapeuticOrPreventiveProcedure | 670 | 679 | A12 | Sumatriptan is a specific migraine treatment which has recently become among the most widely prescribed acute migraine therapies. | 629-771 | 629 | 771 | @SUBJECT$ @PREDICAT$ @OBJECT$ which has recently become among the most widely prescribed acute migraine therapies. |
Fact | preserve | 2552-2554 | 2552-2554 | T172 | in | TREATS | 2,552 | 2,554 | preserve | 2540-2551 | 2540-2551 | T164 | sumatriptan | OrganicChemical | 2,540 | 2,551 | preserve | 2583-2591 | 2583-2591 | T166 | symptoms | SignOrSymptom | 2,583 | 2,591 | A15 | Diclofenac-potassium was generally superior to placebo or sumatriptan in reducing accompanying symptoms, particularly nausea. | 2482-2613 | 2,482 | 2,613 | Diclofenac-potassium was generally superior to placebo or @SUBJECT$ @PREDICAT$ reducing accompanying @OBJECT$ , particularly nausea. |
Fact | preserve | 62-125 | 105-125 | T13 | nonsteroidal anti-inflammatory drug, diclofenac-potassium | TREATS | 62 | 125 | preserve | 105-125 | 105-125 | T7 | diclofenac-potassium | OrganicChemical | 105 | 125 | preserve | 28-35 | 28-35 | T4 | attacks | Finding | 28 | 35 | A17 | Acute treatment of migraine attacks: efficacy and safety of a nonsteroidal anti-inflammatory drug, diclofenac-potassium, in comparison to oral sumatriptan and placebo. | 0-179 | 0 | 179 | Acute treatment of migraine @OBJECT$ : efficacy and safety of a @PREDICAT$ @SUBJECT$ , in comparison to oral sumatriptan and placebo. |
Fact | preserve | 1459-1461 | 1459-1461 | T101 | in | TREATS | 1,459 | 1,461 | preserve | 1400-1407 | 1400-1407 | T88 | placebo | MedicalDevice | 1,400 | 1,407 | preserve | 1472-1480 | 1472-1480 | T92 | patients | PatientOrDisabledGroup | 1,472 | 1,480 | A18 | METHODS: Single oral doses of 50 mg and 100 mg diclofenac-potassium were compared to a single oral dose of 100 mg sumatriptan and placebo in a double-blind randomized crossover trial in 156 adult patients suffering from migraine attacks, with or without aura, selected according to the International Headache Society diagnostic criteria. | 1263-1625 | 1,263 | 1,625 | METHODS: Single oral doses of 50 mg and 100 mg diclofenac-potassium were compared to a single oral dose of 100 mg sumatriptan and @SUBJECT$ in a double-blind randomized crossover trial @PREDICAT$ 156 adult @OBJECT$ suffering from migraine attacks, with or without aura, selected according to the International Headache Society diagnostic criteria. |
Counterfact | preserve | 585-595 | 585-595 | T37 | comparison | compared_with | 585 | 595 | preserve | 441-483 | 478-483 | T31 | nonsteroidal anti-inflammatory drugs | PharmacologicSubstance | 441 | 483 | preserve | 616-627 | 616-627 | T36 | sumatriptan | OrganicChemical | 616 | 627 | A19 | Although also sometimes used to treat migraine, nonsteroidal anti-inflammatory drugs (NSAIDs) have not been systematically evaluated in controlled clinical trials, particularly in comparison with the newer drug sumatriptan. | 393-628 | 393 | 628 | Although also sometimes used to treat migraine, @SUBJECT$ (NSAIDs) have not been systematically evaluated in controlled clinical trials, particularly in @PREDICAT$ with the newer drug @OBJECT$ . |
Fact | preserve | 1991-2019 | 2015-2019 | T138 | migraine headache pain | TREATS | 1,991 | 2,019 | preserve | 1926-1946 | 1926-1946 | T124 | Diclofenac-potassium | OrganicChemical | 1,926 | 1,946 | preserve | 1991-2014 | 2006-2014 | T129 | migraine headache | DiseaseOrSyndrome | 1,991 | 2,014 | A20 | FINDINGS: Diclofenac-potassium was more effective than placebo in reducing migraine headache pain at 2 h after dosing, which was the primary endpoint. | 1910-2072 | 1,910 | 2,072 | FINDINGS: @SUBJECT$ was more effective than placebo in reducing @OBJECT$ @PREDICAT$ at 2 h after dosing, which was the primary endpoint. |
Fact | preserve | 1979-1981 | 1979-1981 | T136 | in | TREATS | 1,979 | 1,981 | preserve | 1971-1978 | 1971-1978 | T127 | placebo | MedicalDevice | 1,971 | 1,978 | preserve | 2015-2019 | 2015-2019 | T130 | pain | SignOrSymptom | 2,015 | 2,019 | A21 | FINDINGS: Diclofenac-potassium was more effective than placebo in reducing migraine headache pain at 2 h after dosing, which was the primary endpoint. | 1910-2072 | 1,910 | 2,072 | FINDINGS: Diclofenac-potassium was more effective than @SUBJECT$ @PREDICAT$ reducing migraine headache @OBJECT$ at 2 h after dosing, which was the primary endpoint. |
Probable | preserve | 270-277 | 270-277 | T28 | treated | TREATS | 270 | 277 | preserve | 315-349 | 337-349 | T25 | ergotamine-containing preparations | OrganicChemical | 315 | 349 | preserve | 252-259 | 252-259 | T20 | attacks | Finding | 252 | 259 | A23 | BACKGROUND: Migraine attacks are often treated with simple analgesics or with ergotamine-containing preparations alone or in combination with anti-emetics. | 231-392 | 231 | 392 | BACKGROUND: Migraine @OBJECT$ are often @PREDICAT$ with simple analgesics or with @SUBJECT$ alone or in combination with anti-emetics. |
Fact | preserve | 1991-2019 | 2015-2019 | T138 | migraine headache pain | TREATS | 1,991 | 2,019 | preserve | 1971-1978 | 1971-1978 | T127 | placebo | MedicalDevice | 1,971 | 1,978 | preserve | 1991-2014 | 2006-2014 | T129 | migraine headache | DiseaseOrSyndrome | 1,991 | 2,014 | A24 | FINDINGS: Diclofenac-potassium was more effective than placebo in reducing migraine headache pain at 2 h after dosing, which was the primary endpoint. | 1910-2072 | 1,910 | 2,072 | FINDINGS: Diclofenac-potassium was more effective than @SUBJECT$ in reducing @OBJECT$ @PREDICAT$ at 2 h after dosing, which was the primary endpoint. |
Fact | preserve | 2673-2675 | 2673-2675 | T191 | as | same_as | 2,673 | 2,675 | preserve | 2614-2634 | 2614-2634 | T176 | Diclofenac-potassium | OrganicChemical | 2,614 | 2,634 | preserve | 2676-2683 | 2676-2683 | T178 | placebo | MedicalDevice | 2,676 | 2,683 | A25 | Diclofenac-potassium seemed to be as well tolerated as placebo, with fewer adverse events reported than after sumatriptan treatment and with more patients assessing the overall tolerability of diclofenac-potassium better than that of sumatriptan. | 2614-2879 | 2,614 | 2,879 | @SUBJECT$ seemed to be as well tolerated @PREDICAT$ @OBJECT$ , with fewer adverse events reported than after sumatriptan treatment and with more patients assessing the overall tolerability of diclofenac-potassium better than that of sumatriptan. |
Fact | preserve | 1966-1970 | 1966-1970 | T133 | than | compared_with | 1,966 | 1,970 | preserve | 1926-1946 | 1926-1946 | T124 | Diclofenac-potassium | OrganicChemical | 1,926 | 1,946 | preserve | 1971-1978 | 1971-1978 | T127 | placebo | MedicalDevice | 1,971 | 1,978 | A26 | FINDINGS: Diclofenac-potassium was more effective than placebo in reducing migraine headache pain at 2 h after dosing, which was the primary endpoint. | 1910-2072 | 1,910 | 2,072 | FINDINGS: @SUBJECT$ was more effective @PREDICAT$ @OBJECT$ in reducing migraine headache pain at 2 h after dosing, which was the primary endpoint. |
Fact | preserve | 2737-2758 | 2749-2758 | T192 | sumatriptan treatment | ISA | 2,737 | 2,758 | preserve | 2737-2748 | 2737-2748 | T181 | sumatriptan | OrganicChemical | 2,737 | 2,748 | preserve | 2749-2758 | 2749-2758 | T182 | treatment | TherapeuticOrPreventiveProcedure | 2,749 | 2,758 | A27 | Diclofenac-potassium seemed to be as well tolerated as placebo, with fewer adverse events reported than after sumatriptan treatment and with more patients assessing the overall tolerability of diclofenac-potassium better than that of sumatriptan. | 2614-2879 | 2,614 | 2,879 | Diclofenac-potassium seemed to be as well tolerated as placebo, with fewer adverse events reported than after @SUBJECT$ @PREDICAT$ @OBJECT$ and with more patients assessing the overall tolerability of diclofenac-potassium better than that of sumatriptan. |
Fact | preserve | 62-125 | 105-125 | T11 | nonsteroidal anti-inflammatory drug, diclofenac-potassium | ISA | 62 | 125 | preserve | 105-125 | 105-125 | T7 | diclofenac-potassium | OrganicChemical | 105 | 125 | preserve | 62-103 | 99-103 | T6 | nonsteroidal anti-inflammatory drug | PharmacologicSubstance | 62 | 103 | A28 | Acute treatment of migraine attacks: efficacy and safety of a nonsteroidal anti-inflammatory drug, diclofenac-potassium, in comparison to oral sumatriptan and placebo. | 0-179 | 0 | 179 | Acute treatment of migraine attacks: efficacy and safety of a @OBJECT$ @PREDICAT$ @SUBJECT$ , in comparison to oral sumatriptan and placebo. |
Fact | preserve | 1966-1970 | 1966-1970 | T134 | than | higher_than | 1,966 | 1,970 | preserve | 1926-1946 | 1926-1946 | T124 | Diclofenac-potassium | OrganicChemical | 1,926 | 1,946 | preserve | 1971-1978 | 1971-1978 | T127 | placebo | MedicalDevice | 1,971 | 1,978 | A29 | FINDINGS: Diclofenac-potassium was more effective than placebo in reducing migraine headache pain at 2 h after dosing, which was the primary endpoint. | 1910-2072 | 1,910 | 2,072 | FINDINGS: @SUBJECT$ was more effective @PREDICAT$ @OBJECT$ in reducing migraine headache pain at 2 h after dosing, which was the primary endpoint. |
Fact | preserve | 2526-2528 | 2526-2528 | T170 | to | higher_than | 2,526 | 2,528 | preserve | 2482-2502 | 2482-2502 | T161 | Diclofenac-potassium | OrganicChemical | 2,482 | 2,502 | preserve | 2529-2536 | 2529-2536 | T163 | placebo | MedicalDevice | 2,529 | 2,536 | A32 | Diclofenac-potassium was generally superior to placebo or sumatriptan in reducing accompanying symptoms, particularly nausea. | 2482-2613 | 2,482 | 2,613 | @SUBJECT$ was generally superior @PREDICAT$ @OBJECT$ or sumatriptan in reducing accompanying symptoms, particularly nausea. |
Fact | preserve | 3169-3178 | 3169-3178 | T219 | reduction | PREVENTS | 3,169 | 3,178 | preserve | 2963-2983 | 2963-2983 | T202 | diclofenac-potassium | OrganicChemical | 2,963 | 2,983 | preserve | 3195-3203 | 3195-3203 | T214 | symptoms | SignOrSymptom | 3,195 | 3,203 | A33 | INTERPRETATION: Compared with placebo and the reference therapy sumatriptan, diclofenac-potassium is an effective, fast-acting, and well-tolerated acute oral therapy for migraine attacks, with advantages over oral sumatriptan in terms of onset of analgesic effect, reduction of accompanying symptoms, and tolerability profile. | 2880-3230 | 2,880 | 3,230 | INTERPRETATION: Compared with placebo and the reference therapy sumatriptan, @SUBJECT$ is an effective, fast-acting, and well-tolerated acute oral therapy for migraine attacks, with advantages over oral sumatriptan in terms of onset of analgesic effect, @PREDICAT$ of accompanying @OBJECT$ , and tolerability profile. |
Fact | preserve | 1481-1490 | 1481-1490 | T103 | suffering | PROCESS_OF | 1,481 | 1,490 | preserve | 1511-1518 | 1511-1518 | T94 | attacks | Finding | 1,511 | 1,518 | preserve | 1472-1480 | 1472-1480 | T92 | patients | PatientOrDisabledGroup | 1,472 | 1,480 | A34 | METHODS: Single oral doses of 50 mg and 100 mg diclofenac-potassium were compared to a single oral dose of 100 mg sumatriptan and placebo in a double-blind randomized crossover trial in 156 adult patients suffering from migraine attacks, with or without aura, selected according to the International Headache Society diagnostic criteria. | 1263-1625 | 1,263 | 1,625 | METHODS: Single oral doses of 50 mg and 100 mg diclofenac-potassium were compared to a single oral dose of 100 mg sumatriptan and placebo in a double-blind randomized crossover trial in 156 adult @OBJECT$ @PREDICAT$ from migraine @SUBJECT$ , with or without aura, selected according to the International Headache Society diagnostic criteria. |
Fact | preserve | 2583-2612 | 2606-2612 | T171 | symptoms, particularly nausea | ISA | 2,583 | 2,612 | preserve | 2606-2612 | 2606-2612 | T167 | nausea | SignOrSymptom | 2,606 | 2,612 | preserve | 2583-2591 | 2583-2591 | T166 | symptoms | SignOrSymptom | 2,583 | 2,591 | A35 | Diclofenac-potassium was generally superior to placebo or sumatriptan in reducing accompanying symptoms, particularly nausea. | 2482-2613 | 2,482 | 2,613 | Diclofenac-potassium was generally superior to placebo or sumatriptan in reducing accompanying @OBJECT$ @PREDICAT$ @SUBJECT$ . |
Fact | preserve | 629-679 | 670-679 | T50 | Sumatriptan is a specific migraine treatment | TREATS | 629 | 679 | preserve | 629-640 | 629-640 | T39 | Sumatriptan | OrganicChemical | 629 | 640 | preserve | 752-760 | 752-760 | T45 | migraine | DiseaseOrSyndrome | 752 | 760 | A36 | Sumatriptan is a specific migraine treatment which has recently become among the most widely prescribed acute migraine therapies. | 629-771 | 629 | 771 | @SUBJECT$ @PREDICAT$ which has recently become among the most widely prescribed acute @OBJECT$ therapies. |
Fact | preserve | 130-140 | 130-140 | T10 | comparison | compared_with | 130 | 140 | preserve | 105-125 | 105-125 | T7 | diclofenac-potassium | OrganicChemical | 105 | 125 | preserve | 144-160 | 149-160 | T8 | oral sumatriptan | OrganicChemical | 144 | 160 | A38 | Acute treatment of migraine attacks: efficacy and safety of a nonsteroidal anti-inflammatory drug, diclofenac-potassium, in comparison to oral sumatriptan and placebo. | 0-179 | 0 | 179 | Acute treatment of migraine attacks: efficacy and safety of a nonsteroidal anti-inflammatory drug, @SUBJECT$ , in @PREDICAT$ to @OBJECT$ and placebo. |
Fact | preserve | 2583-2612 | 2606-2612 | T174 | symptoms, particularly nausea | TREATS | 2,583 | 2,612 | preserve | 2529-2536 | 2529-2536 | T163 | placebo | MedicalDevice | 2,529 | 2,536 | preserve | 2606-2612 | 2606-2612 | T167 | nausea | SignOrSymptom | 2,606 | 2,612 | A41 | Diclofenac-potassium was generally superior to placebo or sumatriptan in reducing accompanying symptoms, particularly nausea. | 2482-2613 | 2,482 | 2,613 | Diclofenac-potassium was generally superior to @SUBJECT$ or sumatriptan in reducing accompanying @PREDICAT$ @OBJECT$ . |
Fact | preserve | 1855-1871 | 1865-1871 | T122 | symptoms (nausea | ISA | 1,855 | 1,871 | preserve | 1865-1871 | 1865-1871 | T119 | nausea | SignOrSymptom | 1,865 | 1,871 | preserve | 1855-1863 | 1855-1863 | T118 | symptoms | SignOrSymptom | 1,855 | 1,863 | A42 | Secondary endpoints included pain at other time points up to 8 h and the presence of accompanying symptoms (nausea, vomiting, photophobia, phonophobia). | 1745-1909 | 1,745 | 1,909 | Secondary endpoints included pain at other time points up to 8 h and the presence of accompanying @OBJECT$ @PREDICAT$ @SUBJECT$ , vomiting, photophobia, phonophobia). |
Possible | preserve | 3295-3298 | 3295-3298 | T227 | for | TREATS | 3,295 | 3,298 | preserve | 3270-3294 | 3287-3294 | T224 | alternative oral therapy | TherapeuticOrPreventiveProcedure | 3,270 | 3,294 | preserve | 3308-3315 | 3308-3315 | T226 | attacks | Finding | 3,308 | 3,315 | A43 | It may therefore be useful as an alternative oral therapy for migraine attacks. | 3231-3316 | 3,231 | 3,316 | It may therefore be useful as an @SUBJECT$ @PREDICAT$ migraine @OBJECT$ . |
Fact | preserve | 2526-2528 | 2526-2528 | T169 | to | compared_with | 2,526 | 2,528 | preserve | 2482-2502 | 2482-2502 | T161 | Diclofenac-potassium | OrganicChemical | 2,482 | 2,502 | preserve | 2529-2536 | 2529-2536 | T163 | placebo | MedicalDevice | 2,529 | 2,536 | A44 | Diclofenac-potassium was generally superior to placebo or sumatriptan in reducing accompanying symptoms, particularly nausea. | 2482-2613 | 2,482 | 2,613 | @SUBJECT$ was generally superior @PREDICAT$ @OBJECT$ or sumatriptan in reducing accompanying symptoms, particularly nausea. |
Fact | preserve | 2583-2612 | 2606-2612 | T174 | symptoms, particularly nausea | TREATS | 2,583 | 2,612 | preserve | 2540-2551 | 2540-2551 | T164 | sumatriptan | OrganicChemical | 2,540 | 2,551 | preserve | 2606-2612 | 2606-2612 | T167 | nausea | SignOrSymptom | 2,606 | 2,612 | A45 | Diclofenac-potassium was generally superior to placebo or sumatriptan in reducing accompanying symptoms, particularly nausea. | 2482-2613 | 2,482 | 2,613 | Diclofenac-potassium was generally superior to placebo or @SUBJECT$ in reducing accompanying @PREDICAT$ @OBJECT$ . |
Fact | preserve | 6-15 | 6-15 | T12 | treatment | TREATS | 6 | 15 | preserve | 62-103 | 99-103 | T6 | nonsteroidal anti-inflammatory drug | PharmacologicSubstance | 62 | 103 | preserve | 28-35 | 28-35 | T4 | attacks | Finding | 28 | 35 | A46 | Acute treatment of migraine attacks: efficacy and safety of a nonsteroidal anti-inflammatory drug, diclofenac-potassium, in comparison to oral sumatriptan and placebo. | 0-179 | 0 | 179 | Acute @PREDICAT$ of migraine @OBJECT$ : efficacy and safety of a @SUBJECT$ , diclofenac-potassium, in comparison to oral sumatriptan and placebo. |
Fact | preserve | 2942-2961 | 2950-2961 | T216 | therapy sumatriptan | ISA | 2,942 | 2,961 | preserve | 2950-2961 | 2950-2961 | T201 | sumatriptan | OrganicChemical | 2,950 | 2,961 | preserve | 2942-2949 | 2942-2949 | T200 | therapy | TherapeuticOrPreventiveProcedure | 2,942 | 2,949 | A48 | INTERPRETATION: Compared with placebo and the reference therapy sumatriptan, diclofenac-potassium is an effective, fast-acting, and well-tolerated acute oral therapy for migraine attacks, with advantages over oral sumatriptan in terms of onset of analgesic effect, reduction of accompanying symptoms, and tolerability profile. | 2880-3230 | 2,880 | 3,230 | INTERPRETATION: Compared with placebo and the reference @OBJECT$ @PREDICAT$ @SUBJECT$ , diclofenac-potassium is an effective, fast-acting, and well-tolerated acute oral therapy for migraine attacks, with advantages over oral sumatriptan in terms of onset of analgesic effect, reduction of accompanying symptoms, and tolerability profile. |
Fact | preserve | 1661-1689 | 1685-1689 | T113 | migraine headache pain | ISA | 1,661 | 1,689 | preserve | 1661-1684 | 1676-1684 | T110 | migraine headache | DiseaseOrSyndrome | 1,661 | 1,684 | preserve | 1685-1689 | 1685-1689 | T111 | pain | SignOrSymptom | 1,685 | 1,689 | A49 | The primary efficacy criterion was migraine headache pain recorded on a visual analog scale at 2 h after dosing. | 1626-1744 | 1,626 | 1,744 | The primary efficacy criterion was @SUBJECT$ @PREDICAT$ @OBJECT$ recorded on a visual analog scale at 2 h after dosing. |
Fact | preserve | 670-679 | 670-679 | T48 | treatment | TREATS | 670 | 679 | preserve | 629-640 | 629-640 | T39 | Sumatriptan | OrganicChemical | 629 | 640 | preserve | 661-669 | 661-669 | T40 | migraine | DiseaseOrSyndrome | 661 | 669 | A50 | Sumatriptan is a specific migraine treatment which has recently become among the most widely prescribed acute migraine therapies. | 629-771 | 629 | 771 | @SUBJECT$ is a specific @OBJECT$ @PREDICAT$ which has recently become among the most widely prescribed acute migraine therapies. |
Fact | preserve | 1979-1981 | 1979-1981 | T136 | in | TREATS | 1,979 | 1,981 | preserve | 1926-1946 | 1926-1946 | T124 | Diclofenac-potassium | OrganicChemical | 1,926 | 1,946 | preserve | 2015-2019 | 2015-2019 | T130 | pain | SignOrSymptom | 2,015 | 2,019 | A52 | FINDINGS: Diclofenac-potassium was more effective than placebo in reducing migraine headache pain at 2 h after dosing, which was the primary endpoint. | 1910-2072 | 1,910 | 2,072 | FINDINGS: @SUBJECT$ was more effective than placebo @PREDICAT$ reducing migraine headache @OBJECT$ at 2 h after dosing, which was the primary endpoint. |
Probable | preserve | 270-277 | 270-277 | T28 | treated | TREATS | 270 | 277 | preserve | 290-300 | 290-300 | T23 | analgesics | PharmacologicSubstance | 290 | 300 | preserve | 252-259 | 252-259 | T20 | attacks | Finding | 252 | 259 | A53 | BACKGROUND: Migraine attacks are often treated with simple analgesics or with ergotamine-containing preparations alone or in combination with anti-emetics. | 231-392 | 231 | 392 | BACKGROUND: Migraine @OBJECT$ are often @PREDICAT$ with simple @SUBJECT$ or with ergotamine-containing preparations alone or in combination with anti-emetics. |
Fact | preserve | 1459-1461 | 1459-1461 | T101 | in | TREATS | 1,459 | 1,461 | preserve | 1384-1395 | 1384-1395 | T87 | sumatriptan | OrganicChemical | 1,384 | 1,395 | preserve | 1472-1480 | 1472-1480 | T92 | patients | PatientOrDisabledGroup | 1,472 | 1,480 | A54 | METHODS: Single oral doses of 50 mg and 100 mg diclofenac-potassium were compared to a single oral dose of 100 mg sumatriptan and placebo in a double-blind randomized crossover trial in 156 adult patients suffering from migraine attacks, with or without aura, selected according to the International Headache Society diagnostic criteria. | 1263-1625 | 1,263 | 1,625 | METHODS: Single oral doses of 50 mg and 100 mg diclofenac-potassium were compared to a single oral dose of 100 mg @SUBJECT$ and placebo in a double-blind randomized crossover trial @PREDICAT$ 156 adult @OBJECT$ suffering from migraine attacks, with or without aura, selected according to the International Headache Society diagnostic criteria. |
Fact | preserve | 2552-2554 | 2552-2554 | T172 | in | TREATS | 2,552 | 2,554 | preserve | 2529-2536 | 2529-2536 | T163 | placebo | MedicalDevice | 2,529 | 2,536 | preserve | 2583-2591 | 2583-2591 | T166 | symptoms | SignOrSymptom | 2,583 | 2,591 | A56 | Diclofenac-potassium was generally superior to placebo or sumatriptan in reducing accompanying symptoms, particularly nausea. | 2482-2613 | 2,482 | 2,613 | Diclofenac-potassium was generally superior to @SUBJECT$ or sumatriptan @PREDICAT$ reducing accompanying @OBJECT$ , particularly nausea. |
Fact | preserve | 1860-1915 | 1902-1915 | T117 | hospitalizations, and other medical interventions | ISA | 1,860 | 1,915 | preserve | 1860-1876 | 1860-1876 | T113 | hospitalizations | HealthCareActivity | 1,860 | 1,876 | preserve | 1902-1915 | 1902-1915 | T115 | interventions | HealthCareActivity | 1,902 | 1,915 | A4 | In pharmacoeconomic studies, lipid-lowering drug therapy has been shown to decrease the number of procedures, hospitalizations, and other medical interventions required by patients with cardiovascular disease. | 1744-1965 | 1,744 | 1,965 | In pharmacoeconomic studies, lipid-lowering drug therapy has been shown to decrease the number of procedures, @SUBJECT$ @PREDICAT$ @OBJECT$ required by patients with cardiovascular disease. |
Fact | preserve | 1447-1520 | 1508-1520 | T99 | lipid-lowering agents currently used are the bile acid sequestrants | ISA | 1,447 | 1,520 | preserve | 1498-1520 | 1508-1520 | T94 | bile acid sequestrants | PharmacologicSubstance | 1,498 | 1,520 | preserve | 1447-1474 | 1468-1474 | T92 | lipid-lowering agents | PharmacologicSubstance | 1,447 | 1,474 | A6 | The principal lipid-lowering agents currently used are the bile acid sequestrants, nicotinic acid, 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitors, and fibric acid derivatives. | 1433-1649 | 1,433 | 1,649 | The principal @OBJECT$ @PREDICAT$ @SUBJECT$ , nicotinic acid, 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitors, and fibric acid derivatives. |
Fact | preserve | 585-604 | 597-604 | T42 | antilipemic therapy | ISA | 585 | 604 | preserve | 585-596 | 585-596 | T33 | antilipemic | PharmacologicSubstance | 585 | 596 | preserve | 597-604 | 597-604 | T34 | therapy | TherapeuticOrPreventiveProcedure | 597 | 604 | A9 | Before starting antilipemic therapy, patients should be evaluated for secondary causes of hyperlipidemia, including disease states and medications. | 569-723 | 569 | 723 | Before starting @SUBJECT$ @PREDICAT$ @OBJECT$ , patients should be evaluated for secondary causes of hyperlipidemia, including disease states and medications. |
Fact | preserve | 585-604 | 597-604 | T44 | antilipemic therapy | USES | 585 | 604 | preserve | 597-604 | 597-604 | T34 | therapy | TherapeuticOrPreventiveProcedure | 597 | 604 | preserve | 585-596 | 585-596 | T33 | antilipemic | PharmacologicSubstance | 585 | 596 | A12 | Before starting antilipemic therapy, patients should be evaluated for secondary causes of hyperlipidemia, including disease states and medications. | 569-723 | 569 | 723 | Before starting @OBJECT$ @PREDICAT$ @SUBJECT$ , patients should be evaluated for secondary causes of hyperlipidemia, including disease states and medications. |
Fact | preserve | 78-85 | 78-85 | T10 | related | COEXISTS_WITH | 78 | 85 | preserve | 55-77 | 70-77 | T5 | Cardiovascular disease | DiseaseOrSyndrome | 55 | 77 | preserve | 89-103 | 89-103 | T6 | hyperlipidemia | DiseaseOrSyndrome | 89 | 103 | A13 | Cardiovascular disease related to hyperlipidemia is a significant cause of morbidity and mortality in the United States. | 55-181 | 55 | 181 | @SUBJECT$ @PREDICAT$ to @OBJECT$ is a significant cause of morbidity and mortality in the United States. |
Fact | preserve | 1788-1806 | 1799-1806 | T119 | drug therapy | USES | 1,788 | 1,806 | preserve | 1773-1806 | 1799-1806 | T110 | lipid-lowering drug therapy | TherapeuticOrPreventiveProcedure | 1,773 | 1,806 | preserve | 1788-1792 | 1788-1792 | T109 | drug | PharmacologicSubstance | 1,788 | 1,792 | A14 | In pharmacoeconomic studies, lipid-lowering drug therapy has been shown to decrease the number of procedures, hospitalizations, and other medical interventions required by patients with cardiovascular disease. | 1744-1965 | 1,744 | 1,965 | In pharmacoeconomic studies, @SUBJECT$ @OBJECT$ @PREDICAT$ has been shown to decrease the number of procedures, hospitalizations, and other medical interventions required by patients with cardiovascular disease. |
Fact | preserve | 1204-1224 | 1216-1224 | T86 | obese patients | PROCESS_OF | 1,204 | 1,224 | preserve | 1204-1209 | 1204-1209 | T72 | obese | DiseaseOrSyndrome | 1,204 | 1,209 | preserve | 1216-1224 | 1216-1224 | T73 | patients | PatientOrDisabledGroup | 1,216 | 1,224 | A16 | Other nonpharmacologic treatments for hyperlipidemia include exercise, weight reduction for obese patients, reduction of excessive alcohol use, and smoking cessation . | 1106-1285 | 1,106 | 1,285 | Other nonpharmacologic treatments for hyperlipidemia include exercise, weight reduction for @SUBJECT$ @PREDICAT$ @OBJECT$ , reduction of excessive alcohol use, and smoking cessation . |
Fact | preserve | 34-38 | 34-38 | T4 | with | PROCESS_OF | 34 | 38 | preserve | 39-53 | 39-53 | T3 | hyperlipidemia | DiseaseOrSyndrome | 39 | 53 | preserve | 25-33 | 25-33 | T2 | patients | PatientOrDisabledGroup | 25 | 33 | A17 | Identifying and managing patients with hyperlipidemia. | 0-54 | 0 | 54 | Identifying and managing @OBJECT$ @PREDICAT$ @SUBJECT$ . |
Fact | preserve | 225-227 | 225-227 | T19 | in | LOCATION_OF | 225 | 227 | preserve | 228-236 | 228-236 | T15 | patients | PatientOrDisabledGroup | 228 | 236 | preserve | 206-211 | 206-211 | T13 | lipid | Lipid | 206 | 211 | A19 | The benefit of lowering lipid levels in patients with and without cardiovascular disease has been demonstrated in numerous clinical trials. | 182-334 | 182 | 334 | The benefit of lowering @OBJECT$ levels @PREDICAT$ @SUBJECT$ with and without cardiovascular disease has been demonstrated in numerous clinical trials. |
Fact | preserve | 704-730 | 723-730 | T49 | beta blocker therapy | USES | 704 | 730 | preserve | 723-730 | 723-730 | T45 | therapy | TherapeuticOrPreventiveProcedure | 723 | 730 | preserve | 704-722 | 715-722 | T44 | beta blocker | PharmacologicSubstance | 704 | 722 | A1 | Ongoing trials are addressing beta blocker therapy in advanced heart failure and comparisons between agents. | 674-788 | 674 | 788 | Ongoing trials are addressing @OBJECT$ @PREDICAT$ @SUBJECT$ in advanced heart failure and comparisons between agents. |
Fact | preserve | 731-733 | 731-733 | T50 | in | TREATS | 731 | 733 | preserve | 723-730 | 723-730 | T45 | therapy | TherapeuticOrPreventiveProcedure | 723 | 730 | preserve | 743-756 | 749-756 | T46 | heart failure | DiseaseOrSyndrome | 743 | 756 | A2 | Ongoing trials are addressing beta blocker therapy in advanced heart failure and comparisons between agents. | 674-788 | 674 | 788 | Ongoing trials are addressing beta blocker @SUBJECT$ @PREDICAT$ advanced @OBJECT$ and comparisons between agents. |
Fact | preserve | 264-266 | 264-266 | T23 | in | TREATS | 264 | 266 | preserve | 232-239 | 232-239 | T15 | therapy | TherapeuticOrPreventiveProcedure | 232 | 239 | preserve | 267-280 | 273-280 | T17 | heart failure | DiseaseOrSyndrome | 267 | 280 | A3 | Beta blocker therapy, once thought heretical in heart failure, has consistently improved cardiac function and slowed progression of disease. | 219-365 | 219 | 365 | Beta blocker @SUBJECT$ , once thought heretical @PREDICAT$ @OBJECT$ , has consistently improved cardiac function and slowed progression of disease. |
Fact | preserve | 23-25 | 23-25 | T3 | in | TREATS | 23 | 25 | preserve | 0-22 | 13-22 | T1 | Beta blocker treatment | TherapeuticOrPreventiveProcedure | 0 | 22 | preserve | 26-39 | 32-39 | T2 | heart failure | DiseaseOrSyndrome | 26 | 39 | A7 | Beta blocker treatment in heart failure. | 0-40 | 0 | 40 | @SUBJECT$ @PREDICAT$ @OBJECT$ . |
Fact | preserve | 219-239 | 232-239 | T22 | Beta blocker therapy | USES | 219 | 239 | preserve | 232-239 | 232-239 | T15 | therapy | TherapeuticOrPreventiveProcedure | 232 | 239 | preserve | 219-231 | 224-231 | T14 | Beta blocker | PharmacologicSubstance | 219 | 231 | A8 | Beta blocker therapy, once thought heretical in heart failure, has consistently improved cardiac function and slowed progression of disease. | 219-365 | 219 | 365 | @OBJECT$ @PREDICAT$ @SUBJECT$ , once thought heretical in heart failure, has consistently improved cardiac function and slowed progression of disease. |
Fact | preserve | 536-538 | 536-538 | T40 | in | TREATS | 536 | 538 | preserve | 499-512 | 504-512 | T31 | Beta blockers | PharmacologicSubstance | 499 | 512 | preserve | 539-558 | 551-558 | T34 | heart failure | DiseaseOrSyndrome | 539 | 558 | A9 | Beta blockers now have stronger data in heart failure than converting enzyme inhibitors, and should be considered standard therapy in mild-moderate heart failure. | 499-673 | 499 | 673 | @SUBJECT$ now have stronger data @PREDICAT$ @OBJECT$ than converting enzyme inhibitors, and should be considered standard therapy in mild-moderate heart failure. |
Fact | preserve | 32-34 | 32-34 | T9 | of | PART_OF | 32 | 34 | preserve | 28-31 | 28-31 | T3 | Vim | GeneOrGenome | 28 | 31 | preserve | 48-56 | 48-56 | T4 | patients | PatientOrDisabledGroup | 48 | 56 | A1 | Neuronal activity in GP and Vim of parkinsonian patients and clinical changes of tremor through surgical interventions. | 0-126 | 0 | 126 | Neuronal activity in GP and @SUBJECT$ @PREDICAT$ parkinsonian @OBJECT$ and clinical changes of tremor through surgical interventions. |
Fact | preserve | 193-196 | 193-196 | T14 | for | TREATS | 193 | 196 | preserve | 165-176 | 165-176 | T11 | pallidotomy | TherapeuticOrPreventiveProcedure | 165 | 176 | preserve | 197-222 | 215-222 | T13 | Parkinson's disease | DiseaseOrSyndrome | 197 | 222 | A2 | Microrecordings were performed during pallidotomy and thalamotomy for Parkinson's disease (PD). | 127-228 | 127 | 228 | Microrecordings were performed during @SUBJECT$ and thalamotomy @PREDICAT$ @OBJECT$ (PD). |
Fact | preserve | 193-196 | 193-196 | T14 | for | TREATS | 193 | 196 | preserve | 181-192 | 181-192 | T12 | thalamotomy | TherapeuticOrPreventiveProcedure | 181 | 192 | preserve | 197-222 | 215-222 | T13 | Parkinson's disease | DiseaseOrSyndrome | 197 | 222 | A3 | Microrecordings were performed during pallidotomy and thalamotomy for Parkinson's disease (PD). | 127-228 | 127 | 228 | Microrecordings were performed during pallidotomy and @SUBJECT$ @PREDICAT$ @OBJECT$ (PD). |
Fact | preserve | 32-34 | 32-34 | T9 | of | PART_OF | 32 | 34 | preserve | 21-23 | 21-23 | T2 | GP | BodyPartOrganOrOrganComponent | 21 | 23 | preserve | 48-56 | 48-56 | T4 | patients | PatientOrDisabledGroup | 48 | 56 | A5 | Neuronal activity in GP and Vim of parkinsonian patients and clinical changes of tremor through surgical interventions. | 0-126 | 0 | 126 | Neuronal activity in @SUBJECT$ and Vim @PREDICAT$ parkinsonian @OBJECT$ and clinical changes of tremor through surgical interventions. |
Fact | preserve | 688-704 | 697-704 | T44 | Pallidal lesions | LOCATION_OF | 688 | 704 | preserve | 688-696 | 688-696 | T35 | Pallidal | BodyPartOrganOrOrganComponent | 688 | 696 | preserve | 697-704 | 697-704 | T36 | lesions | Finding | 697 | 704 | A6 | Pallidal lesions based on microrecording induced relative reductions of tremor, while small Vim lesions immediately alleviated tremor. | 688-835 | 688 | 835 | @SUBJECT$ @PREDICAT$ @OBJECT$ based on microrecording induced relative reductions of tremor, while small Vim lesions immediately alleviated tremor. |
Counterfact | preserve | 1400-1404 | 1400-1404 | T84 | risk | PREDISPOSES | 1,400 | 1,404 | preserve | 1527-1542 | 1537-1542 | T79 | n-3 fatty acids | BiologicallyActiveSubstance | 1,527 | 1,542 | preserve | 1422-1435 | 1429-1435 | T72 | breast cancer | NeoplasticProcess | 1,422 | 1,435 | A1 | When recall bias was taken into consideration, milk was associated with increased risk of premenopausal breast cancer, whereas high consumption of poultry or high intake of monounsaturated fatty acids, n-3 fatty acids, n-6 fatty acids, and vitamin E were related to lower risk. | 1312-1608 | 1,312 | 1,608 | When recall bias was taken into consideration, milk was associated with increased @PREDICAT$ of premenopausal @OBJECT$ , whereas high consumption of poultry or high intake of monounsaturated fatty acids, @SUBJECT$ , n-6 fatty acids, and vitamin E were related to lower risk. |
Possible | preserve | 1777-1789 | 1782-1789 | T101 | risk factors | PREDISPOSES | 1,777 | 1,789 | preserve | 1753-1759 | 1753-1759 | T96 | butter | Food | 1,753 | 1,759 | preserve | 1794-1807 | 1801-1807 | T99 | breast cancer | NeoplasticProcess | 1,794 | 1,807 | A2 | The study suggested that oil, milk, cheese, coffee and beta-carotene may act as protective factors in postmenopausal women, whereas butter and cream may be risk factors for breast cancer. | 1609-1808 | 1,609 | 1,808 | The study suggested that oil, milk, cheese, coffee and beta-carotene may act as protective factors in postmenopausal women, whereas @SUBJECT$ and cream may be @PREDICAT$ for @OBJECT$ . |
Counterfact | preserve | 1400-1404 | 1400-1404 | T84 | risk | PREDISPOSES | 1,400 | 1,404 | preserve | 1571-1580 | 1579-1580 | T81 | vitamin E | Lipid | 1,571 | 1,580 | preserve | 1422-1435 | 1429-1435 | T72 | breast cancer | NeoplasticProcess | 1,422 | 1,435 | A3 | When recall bias was taken into consideration, milk was associated with increased risk of premenopausal breast cancer, whereas high consumption of poultry or high intake of monounsaturated fatty acids, n-3 fatty acids, n-6 fatty acids, and vitamin E were related to lower risk. | 1312-1608 | 1,312 | 1,608 | When recall bias was taken into consideration, milk was associated with increased @PREDICAT$ of premenopausal @OBJECT$ , whereas high consumption of poultry or high intake of monounsaturated fatty acids, n-3 fatty acids, n-6 fatty acids, and @SUBJECT$ were related to lower risk. |
Counterfact | preserve | 1400-1404 | 1400-1404 | T84 | risk | PREDISPOSES | 1,400 | 1,404 | preserve | 1498-1525 | 1520-1525 | T78 | monounsaturated fatty acids | BiologicallyActiveSubstance | 1,498 | 1,525 | preserve | 1422-1435 | 1429-1435 | T72 | breast cancer | NeoplasticProcess | 1,422 | 1,435 | A4 | When recall bias was taken into consideration, milk was associated with increased risk of premenopausal breast cancer, whereas high consumption of poultry or high intake of monounsaturated fatty acids, n-3 fatty acids, n-6 fatty acids, and vitamin E were related to lower risk. | 1312-1608 | 1,312 | 1,608 | When recall bias was taken into consideration, milk was associated with increased @PREDICAT$ of premenopausal @OBJECT$ , whereas high consumption of poultry or high intake of @SUBJECT$ , n-3 fatty acids, n-6 fatty acids, and vitamin E were related to lower risk. |
Counterfact | preserve | 1400-1404 | 1400-1404 | T84 | risk | PREDISPOSES | 1,400 | 1,404 | preserve | 1544-1559 | 1554-1559 | T80 | n-6 fatty acids | BiologicallyActiveSubstance | 1,544 | 1,559 | preserve | 1422-1435 | 1429-1435 | T72 | breast cancer | NeoplasticProcess | 1,422 | 1,435 | A5 | When recall bias was taken into consideration, milk was associated with increased risk of premenopausal breast cancer, whereas high consumption of poultry or high intake of monounsaturated fatty acids, n-3 fatty acids, n-6 fatty acids, and vitamin E were related to lower risk. | 1312-1608 | 1,312 | 1,608 | When recall bias was taken into consideration, milk was associated with increased @PREDICAT$ of premenopausal @OBJECT$ , whereas high consumption of poultry or high intake of monounsaturated fatty acids, n-3 fatty acids, @SUBJECT$ , and vitamin E were related to lower risk. |
Fact | preserve | 1062-1089 | 1077-1081 | T81 | growth factors such as VEGF | ISA | 1,062 | 1,089 | preserve | 1094-1107 | 1094-1107 | T73 | angiopoietins | AminoAcidPeptideOrProtein | 1,094 | 1,107 | preserve | 1062-1076 | 1069-1076 | T71 | growth factors | BiologicallyActiveSubstance | 1,062 | 1,076 | A1 | Since growth factors such as VEGF and angiopoietins and their receptors appear to be necessary for angiogenesis, targeting of growth factor/receptor pathways for angiogenesis-dependent diseases such as glioblastoma might be useful for therapy. | 1056-1311 | 1,056 | 1,311 | Since @OBJECT$ @PREDICAT$ and @SUBJECT$ and their receptors appear to be necessary for angiogenesis, targeting of growth factor/receptor pathways for angiogenesis-dependent diseases such as glioblastoma might be useful for therapy. |
Fact | preserve | 1035-1054 | 1041-1054 | T70 | adult neuroectoderm | PART_OF | 1,035 | 1,054 | preserve | 1041-1054 | 1041-1054 | T66 | neuroectoderm | EmbryonicStructure | 1,041 | 1,054 | preserve | 1035-1040 | 1035-1040 | T65 | adult | AgeGroup | 1,035 | 1,040 | A3 | VEGF is expressed when angiogenesis is high, as in embryonic neuroectoderm, in glioblastomas and around infarcts, but is expressed at low levels when angiogenesis is absent, as in adult neuroectoderm. | 843-1055 | 843 | 1,055 | VEGF is expressed when angiogenesis is high, as in embryonic neuroectoderm, in glioblastomas and around infarcts, but is expressed at low levels when angiogenesis is absent, as in @OBJECT$ @PREDICAT$ @SUBJECT$ . |
Fact | preserve | 432-450 | 444-450 | T35 | brain tumor growth | PART_OF | 432 | 450 | preserve | 438-450 | 444-450 | T31 | tumor growth | NeoplasticProcess | 438 | 450 | preserve | 432-437 | 432-437 | T30 | brain | BodyPartOrganOrOrganComponent | 432 | 437 | A5 | In the rat brain, angiogenesis is complete around postnatal day 20, but endothelial cells can proliferate in the adult brain under pathological conditions such as hypoxia/ischemia and brain tumor growth. | 235-451 | 235 | 451 | In the rat brain, angiogenesis is complete around postnatal day 20, but endothelial cells can proliferate in the adult brain under pathological conditions such as hypoxia/ischemia and @OBJECT$ @PREDICAT$ @SUBJECT$ . |
Fact | preserve | 517-519 | 517-519 | T45 | in | PROCESS_OF | 517 | 519 | preserve | 490-516 | 504-516 | T37 | physiological angiogenesis | PhysiologicFunction | 490 | 516 | preserve | 524-529 | 524-529 | T38 | brain | BodyPartOrganOrOrganComponent | 524 | 529 | A8 | Current evidence suggests that physiological angiogenesis in the brain is regulated by similar mechanisms as pathological angiogenesis induced by tumors or by hypoxia/ischemia. | 452-647 | 452 | 647 | Current evidence suggests that @SUBJECT$ @PREDICAT$ the @OBJECT$ is regulated by similar mechanisms as pathological angiogenesis induced by tumors or by hypoxia/ischemia. |
Fact | preserve | 163-167 | 163-167 | T16 | bind | INTERACTS_WITH | 163 | 167 | preserve | 143-157 | 150-157 | T11 | growth factors | BiologicallyActiveSubstance | 143 | 157 | preserve | 171-196 | 187-196 | T12 | tyrosine kinase receptors | AminoAcidPeptideOrProtein | 171 | 196 | A10 | Brain angiogenesis is a tightly controlled process that is regulated by neuroectodermal derived growth factors that bind to tyrosine kinase receptors expressed on endothelial cells. | 41-234 | 41 | 234 | Brain angiogenesis is a tightly controlled process that is regulated by neuroectodermal derived @SUBJECT$ that @PREDICAT$ to @OBJECT$ expressed on endothelial cells. |
Fact | preserve | 354-365 | 360-365 | T33 | adult brain | PART_OF | 354 | 365 | preserve | 360-365 | 360-365 | T25 | brain | BodyPartOrganOrOrganComponent | 360 | 365 | preserve | 354-359 | 354-359 | T24 | adult | AgeGroup | 354 | 359 | A13 | In the rat brain, angiogenesis is complete around postnatal day 20, but endothelial cells can proliferate in the adult brain under pathological conditions such as hypoxia/ischemia and brain tumor growth. | 235-451 | 235 | 451 | In the rat brain, angiogenesis is complete around postnatal day 20, but endothelial cells can proliferate in the @OBJECT$ @PREDICAT$ @SUBJECT$ under pathological conditions such as hypoxia/ischemia and brain tumor growth. |
Fact | preserve | 41-59 | 47-59 | T14 | Brain angiogenesis | PROCESS_OF | 41 | 59 | preserve | 47-59 | 47-59 | T6 | angiogenesis | OrganOrTissueFunction | 47 | 59 | preserve | 41-46 | 41-46 | T5 | Brain | BodyPartOrganOrOrganComponent | 41 | 46 | A14 | Brain angiogenesis is a tightly controlled process that is regulated by neuroectodermal derived growth factors that bind to tyrosine kinase receptors expressed on endothelial cells. | 41-234 | 41 | 234 | @OBJECT$ @PREDICAT$ @SUBJECT$ is a tightly controlled process that is regulated by neuroectodermal derived growth factors that bind to tyrosine kinase receptors expressed on endothelial cells. |
Fact | preserve | 1443-1452 | 1443-1452 | T105 | induction | AUGMENTS | 1,443 | 1,452 | preserve | 1478-1492 | 1485-1492 | T100 | growth factors | BiologicallyActiveSubstance | 1,478 | 1,492 | preserve | 1456-1468 | 1456-1468 | T99 | angiogenesis | OrganOrTissueFunction | 1,456 | 1,468 | A15 | On the other hand, induction of angiogenesis by growth factors (pro-angiogenesis) might prove to be a rational therapy for patients with stroke. | 1424-1580 | 1,424 | 1,580 | On the other hand, @PREDICAT$ of @OBJECT$ by @SUBJECT$ (pro-angiogenesis) might prove to be a rational therapy for patients with stroke. |
Fact | preserve | 27-29 | 27-29 | T4 | in | PROCESS_OF | 27 | 29 | preserve | 14-26 | 14-26 | T2 | angiogenesis | OrganOrTissueFunction | 14 | 26 | preserve | 34-39 | 34-39 | T3 | brain | BodyPartOrganOrOrganComponent | 34 | 39 | A18 | Mechanisms of angiogenesis in the brain. | 0-40 | 0 | 40 | Mechanisms of @SUBJECT$ @PREDICAT$ the @OBJECT$ . |
Fact | preserve | 1062-1089 | 1077-1081 | T81 | growth factors such as VEGF | ISA | 1,062 | 1,089 | preserve | 1085-1089 | 1085-1089 | T72 | VEGF | AminoAcidPeptideOrProtein | 1,085 | 1,089 | preserve | 1062-1076 | 1069-1076 | T71 | growth factors | BiologicallyActiveSubstance | 1,062 | 1,076 | A19 | Since growth factors such as VEGF and angiopoietins and their receptors appear to be necessary for angiogenesis, targeting of growth factor/receptor pathways for angiogenesis-dependent diseases such as glioblastoma might be useful for therapy. | 1056-1311 | 1,056 | 1,311 | Since @OBJECT$ @PREDICAT$ @SUBJECT$ and angiopoietins and their receptors appear to be necessary for angiogenesis, targeting of growth factor/receptor pathways for angiogenesis-dependent diseases such as glioblastoma might be useful for therapy. |
Fact | preserve | 100-109 | 100-109 | T15 | regulated | AFFECTS | 100 | 109 | preserve | 143-157 | 150-157 | T11 | growth factors | BiologicallyActiveSubstance | 143 | 157 | preserve | 47-59 | 47-59 | T6 | angiogenesis | OrganOrTissueFunction | 47 | 59 | A20 | Brain angiogenesis is a tightly controlled process that is regulated by neuroectodermal derived growth factors that bind to tyrosine kinase receptors expressed on endothelial cells. | 41-234 | 41 | 234 | Brain @OBJECT$ is a tightly controlled process that is @PREDICAT$ by neuroectodermal derived @SUBJECT$ that bind to tyrosine kinase receptors expressed on endothelial cells. |
Fact | preserve | 1568-1572 | 1568-1572 | T107 | with | PROCESS_OF | 1,568 | 1,572 | preserve | 1573-1579 | 1573-1579 | T104 | stroke | DiseaseOrSyndrome | 1,573 | 1,579 | preserve | 1559-1567 | 1559-1567 | T103 | patients | PatientOrDisabledGroup | 1,559 | 1,567 | A21 | On the other hand, induction of angiogenesis by growth factors (pro-angiogenesis) might prove to be a rational therapy for patients with stroke. | 1424-1580 | 1,424 | 1,580 | On the other hand, induction of angiogenesis by growth factors (pro-angiogenesis) might prove to be a rational therapy for @OBJECT$ @PREDICAT$ @SUBJECT$ . |
Fact | preserve | 900-923 | 910-923 | T67 | embryonic neuroectoderm | PART_OF | 900 | 923 | preserve | 910-923 | 910-923 | T58 | neuroectoderm | EmbryonicStructure | 910 | 923 | preserve | 900-909 | 900-909 | T57 | embryonic | EmbryonicStructure | 900 | 909 | A23 | VEGF is expressed when angiogenesis is high, as in embryonic neuroectoderm, in glioblastomas and around infarcts, but is expressed at low levels when angiogenesis is absent, as in adult neuroectoderm. | 843-1055 | 843 | 1,055 | VEGF is expressed when angiogenesis is high, as in @OBJECT$ @PREDICAT$ @SUBJECT$ , in glioblastomas and around infarcts, but is expressed at low levels when angiogenesis is absent, as in adult neuroectoderm. |
Fact | preserve | 242-251 | 246-251 | T32 | rat brain | PART_OF | 242 | 251 | preserve | 246-251 | 246-251 | T18 | brain | BodyPartOrganOrOrganComponent | 246 | 251 | preserve | 242-245 | 242-245 | T17 | rat | Mammal | 242 | 245 | A24 | In the rat brain, angiogenesis is complete around postnatal day 20, but endothelial cells can proliferate in the adult brain under pathological conditions such as hypoxia/ischemia and brain tumor growth. | 235-451 | 235 | 451 | In the @OBJECT$ @PREDICAT$ @SUBJECT$ , angiogenesis is complete around postnatal day 20, but endothelial cells can proliferate in the adult brain under pathological conditions such as hypoxia/ischemia and brain tumor growth. |
Fact | preserve | 1253-1282 | 1262-1266 | T83 | diseases such as glioblastoma | ISA | 1,253 | 1,282 | preserve | 1270-1282 | 1270-1282 | T79 | glioblastoma | NeoplasticProcess | 1,270 | 1,282 | preserve | 1253-1261 | 1253-1261 | T78 | diseases | DiseaseOrSyndrome | 1,253 | 1,261 | A26 | Since growth factors such as VEGF and angiopoietins and their receptors appear to be necessary for angiogenesis, targeting of growth factor/receptor pathways for angiogenesis-dependent diseases such as glioblastoma might be useful for therapy. | 1056-1311 | 1,056 | 1,311 | Since growth factors such as VEGF and angiopoietins and their receptors appear to be necessary for angiogenesis, targeting of growth factor/receptor pathways for angiogenesis-dependent @OBJECT$ @PREDICAT$ @SUBJECT$ might be useful for therapy. |
Fact | preserve | 1969-1985 | 1978-1985 | T106 | valvular disease | LOCATION_OF | 1,969 | 1,985 | preserve | 1969-1977 | 1969-1977 | T98 | valvular | BodyPartOrganOrOrganComponent | 1,969 | 1,977 | preserve | 1978-1985 | 1978-1985 | T99 | disease | DiseaseOrSyndrome | 1,978 | 1,985 | A1 | This simple diagnostic tool, along with a careful history and medical examination, would hopefully prevent the misinterpretation of confusing clinical findings and would help to identify the patients with normal systolic function or valvular disease such as critical aortic stenosis, where digoxin treatment would not be warranted. | 1716-2074 | 1,716 | 2,074 | This simple diagnostic tool, along with a careful history and medical examination, would hopefully prevent the misinterpretation of confusing clinical findings and would help to identify the patients with normal systolic function or @SUBJECT$ @PREDICAT$ @OBJECT$ such as critical aortic stenosis, where digoxin treatment would not be warranted. |
Fact | preserve | 1048-1055 | 1048-1055 | T58 | related | COEXISTS_WITH | 1,048 | 1,055 | preserve | 1028-1047 | 1040-1047 | T50 | heart failure | DiseaseOrSyndrome | 1,028 | 1,047 | preserve | 1068-1096 | 1085-1096 | T52 | left ventricular dysfunction | PathologicFunction | 1,068 | 1,096 | A3 | Currently, the use of digoxin can be advocated to control heart failure in atrial fibrillation and when added to ACE inhibitors and diuretics in those patients with symptomatic heart failure related to systolic left ventricular dysfunction. | 839-1097 | 839 | 1,097 | Currently, the use of digoxin can be advocated to control heart failure in atrial fibrillation and when added to ACE inhibitors and diuretics in those patients with symptomatic @SUBJECT$ @PREDICAT$ to systolic @OBJECT$ . |
Fact | preserve | 993-995 | 993-995 | T55 | in | TREATS | 993 | 995 | preserve | 983-992 | 983-992 | T47 | diuretics | PharmacologicSubstance | 983 | 992 | preserve | 1028-1047 | 1040-1047 | T50 | heart failure | DiseaseOrSyndrome | 1,028 | 1,047 | A4 | Currently, the use of digoxin can be advocated to control heart failure in atrial fibrillation and when added to ACE inhibitors and diuretics in those patients with symptomatic heart failure related to systolic left ventricular dysfunction. | 839-1097 | 839 | 1,097 | Currently, the use of digoxin can be advocated to control heart failure in atrial fibrillation and when added to ACE inhibitors and @SUBJECT$ @PREDICAT$ those patients with symptomatic @OBJECT$ related to systolic left ventricular dysfunction. |
Fact | preserve | 2290-2306 | 2300-2306 | T118 | patient's gender | PROCESS_OF | 2,290 | 2,306 | preserve | 2300-2306 | 2300-2306 | T116 | gender | OrganismAttribute | 2,300 | 2,306 | preserve | 2290-2299 | 2290-2297 | T115 | patient's | PatientOrDisabledGroup | 2,290 | 2,299 | A5 | If it is necessary to administer digoxin, then the likelihood of significant toxicity can be greatly reduced by using an algorithm to calculate the appropriate dosage, which takes into consideration the patient's gender, bodyweight and creatinine clearance. | 2075-2350 | 2,075 | 2,350 | If it is necessary to administer digoxin, then the likelihood of significant toxicity can be greatly reduced by using an algorithm to calculate the appropriate dosage, which takes into consideration the @OBJECT$ @PREDICAT$ @SUBJECT$ , bodyweight and creatinine clearance. |
Fact | preserve | 917-919 | 917-919 | T54 | in | COEXISTS_WITH | 917 | 919 | preserve | 903-916 | 909-916 | T44 | heart failure | DiseaseOrSyndrome | 903 | 916 | preserve | 920-939 | 927-939 | T45 | atrial fibrillation | PathologicFunction | 920 | 939 | A6 | Currently, the use of digoxin can be advocated to control heart failure in atrial fibrillation and when added to ACE inhibitors and diuretics in those patients with symptomatic heart failure related to systolic left ventricular dysfunction. | 839-1097 | 839 | 1,097 | Currently, the use of digoxin can be advocated to control @SUBJECT$ @PREDICAT$ @OBJECT$ and when added to ACE inhibitors and diuretics in those patients with symptomatic heart failure related to systolic left ventricular dysfunction. |
Fact | preserve | 1232-1242 | 1232-1242 | T73 | prevalence | OCCURS_IN | 1,232 | 1,242 | preserve | 1246-1269 | 1262-1269 | T67 | diastolic heart failure | DiseaseOrSyndrome | 1,246 | 1,269 | preserve | 1277-1284 | 1277-1284 | T68 | elderly | AgeGroup | 1,277 | 1,284 | A7 | It is likely that the excessive use of digoxin in elderly populations as discussed in this review is perhaps based on the prevalence of diastolic heart failure in the elderly as well as other co-morbid conditions that may mimic heart failure signs and symptoms. | 1098-1377 | 1,098 | 1,377 | It is likely that the excessive use of digoxin in elderly populations as discussed in this review is perhaps based on the @PREDICAT$ of @SUBJECT$ in the @OBJECT$ as well as other co-morbid conditions that may mimic heart failure signs and symptoms. |
Probable | preserve | 2421-2426 | 2421-2426 | T131 | treat | TREATS | 2,421 | 2,426 | preserve | 2406-2413 | 2406-2413 | T120 | digoxin | Carbohydrate | 2,406 | 2,413 | preserve | 2427-2451 | 2444-2451 | T121 | congestive heart failure | DiseaseOrSyndrome | 2,427 | 2,451 | A8 | Although it is probable that the indications for digoxin use to treat congestive heart failure will continue to evolve, at the present time most would recommend using this agent in symptomatic heart failure related to a reduction in left ventricular systolic function or when associated with atrial fibrillation. | 2351-2687 | 2,351 | 2,687 | Although it is probable that the indications for @SUBJECT$ use to @PREDICAT$ @OBJECT$ will continue to evolve, at the present time most would recommend using this agent in symptomatic heart failure related to a reduction in left ventricular systolic function or when associated with atrial fibrillation. |
Fact | preserve | 1011-1015 | 1011-1015 | T57 | with | PROCESS_OF | 1,011 | 1,015 | preserve | 1028-1047 | 1040-1047 | T50 | heart failure | DiseaseOrSyndrome | 1,028 | 1,047 | preserve | 1002-1010 | 1002-1010 | T48 | patients | PatientOrDisabledGroup | 1,002 | 1,010 | A9 | Currently, the use of digoxin can be advocated to control heart failure in atrial fibrillation and when added to ACE inhibitors and diuretics in those patients with symptomatic heart failure related to systolic left ventricular dysfunction. | 839-1097 | 839 | 1,097 | Currently, the use of digoxin can be advocated to control heart failure in atrial fibrillation and when added to ACE inhibitors and diuretics in those @OBJECT$ @PREDICAT$ symptomatic @SUBJECT$ related to systolic left ventricular dysfunction. |
Fact | preserve | 993-995 | 993-995 | T55 | in | TREATS | 993 | 995 | preserve | 964-978 | 968-978 | T46 | ACE inhibitors | PharmacologicSubstance | 964 | 978 | preserve | 1002-1010 | 1002-1010 | T48 | patients | PatientOrDisabledGroup | 1,002 | 1,010 | A10 | Currently, the use of digoxin can be advocated to control heart failure in atrial fibrillation and when added to ACE inhibitors and diuretics in those patients with symptomatic heart failure related to systolic left ventricular dysfunction. | 839-1097 | 839 | 1,097 | Currently, the use of digoxin can be advocated to control heart failure in atrial fibrillation and when added to @SUBJECT$ and diuretics @PREDICAT$ those @OBJECT$ with symptomatic heart failure related to systolic left ventricular dysfunction. |
Fact | preserve | 545-590 | 580-590 | T30 | digoxin is a frequently prescribed medication | ISA | 545 | 590 | preserve | 545-552 | 545-552 | T24 | digoxin | Carbohydrate | 545 | 552 | preserve | 580-590 | 580-590 | T27 | medication | PharmacologicSubstance | 580 | 590 | A11 | Over the years, it has been documented that digoxin is a frequently prescribed medication in elderly populations. | 495-620 | 495 | 620 | Over the years, it has been documented that @SUBJECT$ @PREDICAT$ @OBJECT$ in elderly populations. |
Uncommitted | preserve | 1631-1640 | 1631-1640 | T87 | performed | ADMINISTERED_TO | 1,631 | 1,640 | preserve | 1598-1614 | 1598-1614 | T83 | echocardiography | DiagnosticProcedure | 1,598 | 1,614 | preserve | 1657-1665 | 1657-1665 | T85 | patients | PatientOrDisabledGroup | 1,657 | 1,665 | A12 | It is proposed that echocardiography should be performed in most elderly patients when congestive heart failure is suspected. | 1578-1715 | 1,578 | 1,715 | It is proposed that @SUBJECT$ should be @PREDICAT$ in most elderly @OBJECT$ when congestive heart failure is suspected. |
Fact | preserve | 29-31 | 29-31 | T6 | in | TREATS | 29 | 31 | preserve | 21-28 | 21-28 | T3 | digoxin | Carbohydrate | 21 | 28 | preserve | 36-43 | 36-43 | T4 | elderly | AgeGroup | 36 | 43 | A13 | Inappropriate use of digoxin in the elderly: how widespread is the problem and how can it be solved? | 0-106 | 0 | 106 | Inappropriate use of @SUBJECT$ @PREDICAT$ the @OBJECT$ : how widespread is the problem and how can it be solved? |
Fact | preserve | 1978-2018 | 1986-1990 | T105 | disease such as critical aortic stenosis | ISA | 1,978 | 2,018 | preserve | 2003-2018 | 2010-2018 | T101 | aortic stenosis | DiseaseOrSyndrome | 2,003 | 2,018 | preserve | 1978-1985 | 1978-1985 | T99 | disease | DiseaseOrSyndrome | 1,978 | 1,985 | A14 | This simple diagnostic tool, along with a careful history and medical examination, would hopefully prevent the misinterpretation of confusing clinical findings and would help to identify the patients with normal systolic function or valvular disease such as critical aortic stenosis, where digoxin treatment would not be warranted. | 1716-2074 | 1,716 | 2,074 | This simple diagnostic tool, along with a careful history and medical examination, would hopefully prevent the misinterpretation of confusing clinical findings and would help to identify the patients with normal systolic function or valvular @OBJECT$ @PREDICAT$ @SUBJECT$ , where digoxin treatment would not be warranted. |
Probable | preserve | 895-902 | 895-902 | T53 | control | TREATS | 895 | 902 | preserve | 867-874 | 867-874 | T43 | digoxin | Carbohydrate | 867 | 874 | preserve | 903-916 | 909-916 | T44 | heart failure | DiseaseOrSyndrome | 903 | 916 | A15 | Currently, the use of digoxin can be advocated to control heart failure in atrial fibrillation and when added to ACE inhibitors and diuretics in those patients with symptomatic heart failure related to systolic left ventricular dysfunction. | 839-1097 | 839 | 1,097 | Currently, the use of @SUBJECT$ can be advocated to @PREDICAT$ @OBJECT$ in atrial fibrillation and when added to ACE inhibitors and diuretics in those patients with symptomatic heart failure related to systolic left ventricular dysfunction. |